MADDEN SECURITIES Corp Buys Shares of 30,999 Pfizer Inc. (NYSE:PFE)
MADDEN SECURITIES Corp purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 30,999 shares of the biopharmaceutical company’s stock, valued at approximately $1,014,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Monte Financial Group LLC lifted its position in shares of Pfizer by 540.9% during the 1st quarter. Monte Financial Group LLC now owns 93,388 shares of the biopharmaceutical company’s stock worth $3,048,000 after purchasing an additional 78,816 shares during the last quarter. CA Family Wealth LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $326,000. Sanders Morris Harris LLC lifted its stake in shares of Pfizer by 27.0% in the 1st quarter. Sanders Morris Harris LLC now owns 31,823 shares of the biopharmaceutical company’s stock valued at $580,000 after purchasing an additional 6,775 shares during the period. Keebeck Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $239,000. Finally, 1832 Asset Management L.P. lifted its stake in shares of Pfizer by 1.6% in the 4th quarter. 1832 Asset Management L.P. now owns 9,242,544 shares of the biopharmaceutical company’s stock valued at $361,518,000 after purchasing an additional 147,381 shares during the period. 70.20% of the stock is owned by institutional investors and hedge funds.
In other Pfizer news, SVP Jennifer B. Damico sold 2,181 shares of the stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $38.35, for a total value of $83,641.35. Following the sale, the senior vice president now directly owns 9,647 shares in the company, valued at approximately $369,962.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Douglas M. Lankler sold 65,000 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total transaction of $2,460,250.00. Following the completion of the sale, the executive vice president now owns 135,375 shares in the company, valued at $5,123,943.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,362 shares of company stock valued at $2,622,691. 0.08% of the stock is owned by insiders.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.09. The firm had revenue of $12.03 billion during the quarter, compared to the consensus estimate of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. The company’s revenue was down 8.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.85 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.88 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 31st will be issued a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 4.31%. The ex-dividend date of this dividend is Thursday, July 30th. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.
Several research firms have issued reports on PFE. SVB Leerink assumed coverage on Pfizer in a research note on Tuesday, June 16th. They issued a “market perform” rating and a $40.00 price target on the stock. Cantor Fitzgerald restated a “buy” rating and set a $53.00 price objective on shares of Pfizer in a research report on Thursday, March 19th. Barclays lowered their price objective on shares of Pfizer from $37.00 to $35.00 in a research report on Monday, June 1st. JPMorgan Chase & Co. decreased their target price on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Monday, June 1st. Finally, Morgan Stanley decreased their target price on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 2nd. Ten analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $38.72.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: Profit Margin
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.